John Lin

John Lin, MD, PhD, joined Regeneron in 2016 and oversees the preclinical bispecific antibody research work in Research and Development across all disease areas. Previously, Dr. Lin worked at Pfizer for 10 years focusing on research and early development of biologics, and before that he worked at Rinat Neuroscience Corporation after completing his postdoctoral fellowship at Genentech. Dr. Lin received his MD from National Taiwan University and his PhD from Harvard University.